SC-60

SC-60 is a derivative of Sorafenib (HY-10201) . SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC[1].

Product Specifications

CAS Number

[1421677-31-7]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; CDK; Drug Derivative; SHP1; STAT; Survivin

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

N#CC1=CC=C(C=C1)OC2=CC(NC(NC3=CC=C(C)C(OC4=CC=C(C=C4)C#N)=C3)=O)=CC=C2C

Molecular Formula

C29H22N4O3

Molecular Weight

474.51

References & Citations

[1]Tai WT, et al. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. Mol Cancer Ther. 2014 Jan;13 (1) :27-36.